Valuation: Daxor Corporation

Market Cap 62M 55.09M 51.42M 46.86M 88.39M 5.96B 89.21M 622M 241M 3.05B 233M 228M 9.78B P/E 2026 *
-50.6x
P/E 2027 * -354x
Enterprise Value 62M 55.09M 51.42M 46.86M 88.39M 5.96B 89.21M 622M 241M 3.05B 233M 228M 9.78B EV / Sales 2026 *
6.67x
EV / Sales 2027 * 3.78x
Free-Float
46.7%
Yield 2026 *
-
Yield 2027 * -
1 week-3.54%
Current month-5.60%
1 month-1.12%
3 months+2.31%
6 months+9.48%
Current year-28.00%
1 week 10.44
Extreme 10.4401
11.86
1 month 9.9
Extreme 9.9
12.25
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2013
Director of Finance/CFO 69 28/09/2018
Chief Tech/Sci/R&D Officer - 05/06/2024
Director TitleAgeSince
Director/Board Member 91 01/01/1989
Chairman 56 14/02/2017
Director/Board Member 70 22/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
-3.28%-5.01%-24.14% - 62M
-0.73%-3.52%+5.37%+121.66% 15.13B
-0.26%-6.95%+24.05%+168.91% 11.89B
+1.10%-1.24%-21.08%+23.27% 8.48B
-0.62%-4.67%+12.99%+144.72% 7.27B
+1.77%+2.86%-27.42%-14.89% 6.86B
+1.37%+1.79%-2.36%+20.56% 6.6B
-0.39%-0.64%+7.34%+28.52% 4.73B
+0.92%-1.51% - - 3.71B
+2.90%-2.35%-3.82%+4.70% 3.61B
Average +0.67%-1.61%-3.23%+62.18% 7.59B
Weighted average by Cap. +0.35%-2.24%+1.53%+81.84%

Financials

2026 *2027 *
Net sales 9.3M 8.26M 7.71M 7.03M 13.26M 894M 13.38M 93.33M 36.17M 457M 34.92M 34.16M 1.47B 16.4M 14.57M 13.6M 12.4M 23.38M 1.58B 23.6M 165M 63.78M 806M 61.57M 60.24M 2.59B
Net income -1.2M -1.07M -995K -907K -1.71M -115M -1.73M -12.04M -4.67M -58.97M -4.51M -4.41M -189M -200K -178K -166K -151K -285K -19.23M -288K -2.01M -778K -9.83M -751K -735K -31.54M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
-
Date Price Change Volume
02/10/26 US$10.62 -3.28% 8,233
01/10/26 US$10.98 -2.40% 16,091
30/09/26 US$11.25 -3.85% 29,970
29/09/26 US$11.70 +3.08% 34,262
28/09/26 US$11.35 +3.09% 11,713
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.62USD
Average target price
20.00USD
Spread / Average Target
+88.32%

Quarterly revenue - Rate of surprise